Paper Details

  1. Home
  2. Paper Details

Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study.

Author: ImaiKojiro, KasaharaTakeru, KawasakiTakanori, MatobaSatoaki, NakanishiNaohiko, OkadaTakashi, SawadaTakahisa, TakaiShigeki, YamadaAyumu, YokotaIsao

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the clot regression effects of rivaroxaban, a direct oral anticoagulant, in patients with cancer-associated venous thromboembolism (CAT). The results show that rivaroxaban significantly reduced clot volume and achieved a high clot-regression rate, suggesting its efficacy in treating CAT. However, the study also highlights the importance of monitoring for bleeding complications.
Paper Details　
Original Abstract of the Article :
Rivaroxaban, a direct oral anticoagulant, is effective against venous thromboembolism (VTE) recurrence without increasing the risk of major bleeding in patients with cancer-associated venous thromboembolism (CAT). However, its clot regression effects are poorly understood. This single-arm, prospecti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747974/

データ提供：米国国立医学図書館（NLM）

Rivaroxaban for Clot Regression in Venous Thromboembolism

The treatment of venous thromboembolism (VTE) in cancer patients is like navigating a challenging desert landscape. This prospective interventional study explores the clot-regression effects of rivaroxaban, a direct oral anticoagulant, in patients with cancer-associated VTE (CAT). Researchers, like skilled engineers, are seeking to understand how rivaroxaban can help dissolve blood clots. The results show that rivaroxaban effectively reduced clot volume in CAT patients, demonstrating its potential for improving outcomes in this challenging patient population.

Rivaroxaban: A Potential Solution for Clot Regression

This study, like a refreshing oasis, offers hope and guidance for CAT patients. It highlights the potential of rivaroxaban in effectively reducing clot volume. The researchers, like skilled builders, are demonstrating that this medication can help patients overcome the challenges of CAT.

Rivaroxaban: A Journey to Healthier Blood Flow

The desert of blood clots can be a dangerous and debilitating place. This study, like a guiding star, offers hope and direction. It highlights the potential of rivaroxaban in helping patients navigate this challenging terrain, promoting healthier blood flow and improving their overall well-being.

Dr.Camel's Conclusion

The desert of blood clots can be a daunting place for patients with cancer-associated VTE. This study offers valuable insights into the potential of rivaroxaban in promoting clot regression, providing hope and guidance for individuals navigating this challenging terrain.

Date :
  1. Date Completed 2022-12-15
  2. Date Revised 2023-01-15
Further Info :

Pubmed ID

36513734

DOI: Digital Object Identifier

PMC9747974

Related Literature

Article Analysis
・Effects of rivaroxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.